Display Settings:

Items per page

Results: 6

1.
Figure 1

Figure 1. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

(a) Synthetic scheme of Phe-OCA monomer and the structure of (BDI-EI)ZnN(TMS)2 catalyst. (b) Schematic illustration of (BDI-EI)ZnN(TMS)2/Cpt mediated ring-opening polymerization (ROP) of Phe-OCA followed by formulation of Cpt-PheLAn nanoconjugates (NCs, n = the feed ratio of Phe-OCA/Cpt) using nanoprecipitation. (c) Chemical structures of hydroxyl-containing paclitaxel, doxorubicin and docetaxel.

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.
2.
Figure 2

Figure 2. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

(a) (BDI-EI)ZnN(TMS)2/Cpt mediated controlled ring-opening polymerization (ROP) of Phe-OCA at various Phe-OCA/Cpt ratios (MWD = molecular weight distribution). (b) Overlay of the GPC traces of Cpt-PheLAn (n = 25, 50 and 100). (c) HPLC analysis of Cpt-initiated polymerization and release of Cpt from Cpt-PheLA100 NCs. (i) authentic Cpt. (ii) the Phe-OCA polymerization solution (M/I = 100) mediated by (BDI-EI)ZnNTMS and Cpt. (iii) Cpt released from Cpt-PheLA100 NCs treated with 1 M NaOH for 12 h.

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.
3.
Figure 6

Figure 6. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

(a) Cytotoxicity of blank PheLA100 NCs and PEGylated PheLA100 NCs in MCF-7 cells over 72 h at 37°C, determined by MTT assays. (b) Histopathology analysis of mouse tissues following an i.v. injection of PEGylated PheLA100 NCs via tail vein. Representative sections of various organs taken from the control mice receiving PBS and the treatment mice receiving 250 mg/kg PEGylated PheLA100 NCs 24 h post injection were stained by hematoxylin and eosin. No organs of the mice given PEGylated PheLA100 NCs showed acute inflammations.

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.
4.
Figure 3

Figure 3. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

Formulation and characterization of Cpt-PheLAn NCs. (a) Dynamic light scattering (DLS) analysis of Cpt-PheLA100 NCs in water (0.5 mg/mL) and TEM image of Cpt-PheLA100 NCs (negative stained). (b) DLS analysis of NC reconstitution. (i) Cpt-PheLA100 NCs mixed with human serum albumin (HSA) in water before lyophilization. (ii) The reconstituted Cpt-PheLA100 NCs after lyophilization in the presence of HSA (HSA:NC = 10:1, w/w). (c) Release kinetic profiles of Cpt-PheLAn NCs (n = 25, 50 and 100) versus Cpt/mPEG-PheLA100 encapsulated NPs in human serum buffer (human serum:PBS = 1:1, v/v). (d) Cytotoxicity of various Cpt-PheLAn NCs (n = 25, 50 and 100) and free Cpt in MCF-7 cells (72 h, 37 °C).

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.
5.
Figure 4

Figure 4. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

(a) Stability of PEGylated Cpt-PheLA25 NCs versus PEGylated Cpt-PLA25 NCs in human serum buffer (human serum:PBS = 1:1, v/v). (b) CMC determination of mPEG5k-PheLA100 and mPEG5k-LA100. Intensity of Nile Red versus concentrations of mPEG5k-PheLA100 and mPEG5k-PLA100. The CMC was determined by taking the midpoint in the plots, which was 2.2 × 10−2 mg/mL and 4.5 × 10−2 mg/mL, respectively. (c) The particle size changes of PEGylated PheLA100 NCs and PEGylated LA100 NCs with/without dilution as determined by dynamic light scattering (DLS). The original concentration of NC was 0.5 mg/mL. (d) Proposed changes of core-shell nanostructure of PEGylated PheLAn and PEGylated LAn NPs upon dilution after injection into the body: (i) PEGylated PheLAn NCs, stable micellar structure due to enhanced non-covalent interactions (hydrophobic interactions and π-π stacking) in the polymeric core preventing rapid dissolution of core-shell nanostructure in vivo. (ii) PEGylated LAn NCs, loosely packed polymeric core disrupted upon dilution. Orange star = drug cargos; blue line = PheLA/PLA polymer chain; green line = PEG.

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.
6.
Figure 5

Figure 5. From: Drug-Initiated Ring-Opening Polymerization of O-Carboxyanhydrides for the Preparation of Anticancer Drug-Poly(O-Carboxyanhydride) Nanoconjugates.

(a) Schematic illustration of synthesis and formulation of 64Cu-labelled PEGylated PheLA NCs and PLA NCs. (b) Six athymic nude mice were divided into two groups (n = 3) and injected 64Cu-labelled PEGylated PheLA100 NCs and 64Cu-labeled PEGylated PLA100 NCs via i.v. injection, respectively. Mice were taken blood intraorbitally at different time points (0 h, 0.5 h, 1 h, 2 h, 5 h, 10 h, and 22 h) and the radioactivity in blood was determined using γ-counter. Statistical significance analysis were assessed by Two-Sample Unpaired Student's t-test; 0.01 < p ≤ 0.05 and p ≤ 0.01 are considered statistically significant and highly significant and are denoted as “*” and “**” respectively, in the figure. (c) Six athymic nude mice were divided into two groups (n = 3) and injected 64Cu labelled PEGylated PheLA100 NCs and PLA100 NCs via i.v. injection, respectively. Mice were euthanized after 24 h and the major organs were collected. The radioactivity in each organ was determined using γ-counter. The fidelity of utilizing γ-counter for quantitative radioactivity analysis in biological tissues was verified in a series of control studies. All the organ distribution were presented as percentage of injected dose per gram of tissue (% I.D./g tissue).

Qian Yin, et al. Biomacromolecules. ;14(3):920-929.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk